NCT01891994View on ClinicalTrials.gov

Extended Dosing With Eltrombopag for Severe Aplastic Anemia

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

June 28, 2013

Primary Completion Date

October 16, 2017

Study Completion Date

August 24, 2022

Conditions
Severe Aplastic Anemia (SAA)
Interventions
DRUG

Eltrombopag

Oral administration of eltrombopag 150mg/day (75 mg/day for East Asian ancestry) for 6 months

Trial Locations (1)

20892

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda

All Listed Sponsors
lead

National Heart, Lung, and Blood Institute (NHLBI)

NIH

NCT01891994 - Extended Dosing With Eltrombopag for Severe Aplastic Anemia | Biotech Hunter | Biotech Hunter